查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020211

處方藥市場規模、佔有率、成長率及全球產業分析：按類型、應用和地區的洞察，2026-2034年的預測

Prescription Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 140 Pages | 商品交期: 請詢問到貨日

價格

處方藥市場的成長要素

全球處方藥市場在2025年達到13,244.4億美元，預計2026年成長至1,4155.2億美元，並在2034年達到2,4928.4億美元。這意味著在預測期內，該市場將維持7.33%的強勁年複合成長率。北美在2025年佔據市場主導地位，市場佔有率高達49.66%，這主要得益於其高昂的醫療保健支出、先進的治療方法以及著重學名藥和專科藥物的大型製藥企業的存在。光是美國處方藥市場預計到2032年就將達到9.311億美元，這主要得益於孤兒藥核准的增加以及對專科藥物需求的成長。

處方藥包括疫苗、生物製藥以及用於治療癌症、心血管疾病、糖尿病和罕見疾病（孤兒病）等急性慢性疾病的治療方法。近年來，市場發生了顯著變化，包括學名藥的湧入，這影響了整體市場滲透率和可及性。2020年，新冠疫情導致市場暫時萎縮，原因是封鎖措施、醫院就診限制和供應鏈中斷，造成全球藥品短缺和藥品支出下降。根據美國衛生系統藥劑師協會統計，2020年非聯邦醫院的處方藥支出下降了4.6%。然而，常規醫療服務的重新開放、病患就診量的增加以及研發投入的活性化，特別是針對新冠肺炎治療的研發投入，都促進了市場的復甦。

市場趨勢

拓展跨治療領域的研發管線

製藥公司加大研發投入是重要的市場趨勢。2021年，歐洲以研發為主導的製藥公司在慢性病治療藥物的研發上投入了約436.842億美元。各公司正日益關注孤兒藥，並進行了大量臨床試驗。預計這將推動市場在預測期內成長。

學名藥的普及

非專利處方藥的上市是成長要素之一。2019年10月，美國FDA核准了1,171種非專利處方藥，促進了市場競爭，降低了藥品價格。政府主導的舉措，例如印度的Aushadhi Scheme，使得非專利處方藥的價格比原廠藥低50%至90%，進一步促進了市場擴張。

罕見疾病孤兒藥的研發

另一個重要因素是人們對孤兒藥日益成長的關注。像BioMarin和Baudax Bio這樣的公司研發罕見疾病療法，孤兒藥的核准加速了臨床試驗，最終使藥物得以進入市場，並為此前服務不足的市場創造重磅藥物的機會。

市場限制因素

儘管存在成長要素，但處方藥的高成本限制了其市場滲透率。研發新藥的成本可能高達26億美元，而某些治療方法，例如前列腺癌藥物Abiraterone，每月費用可能高達1萬美元，這使得藥物的可及性難以負擔，尤其是在發展中地區。

市場區隔

依產品類型

  • 其他處方藥佔據市場主導地位，預計到2026年將佔全球整體的71.71%。這主要是由於腫瘤藥物、抗糖尿病藥物和心血管藥物的普及，而這些藥物的學名藥目前尚未廣泛上市。
  • 孤兒藥預計將以更高的年複合成長率成長，這得益於臨床試驗的增加和監管核准的擴大。
  • 學名藥因其價格低廉且在新興市場越來越受歡迎而受益。

依治療領域

  • 腫瘤學領域處於主導，由於癌症的高發生率和標靶治療的核准，預計到2026年，腫瘤學將佔全球整體的67.55%。
  • 其他細分市場包括中樞神經系統藥物、疫苗和免疫抑制劑，所有這些市場預計都會因疾病盛行率上升和監管部門核准而成長。

依通路

  • 由於重要藥物通常需要專門的給藥方式，因此醫院藥局是這些藥物的主要來源。
  • 零售藥局和網路藥局都在發展，由於處方箋續藥的便利性，預計網路藥局的年複合成長率將最高。

區域趨勢

  • 北美：受先進治療方法和高額醫療保健支出的推動，2025年市場規模達到6,576.8億美元，預計2026年將達到7,030.4億美元。其中，美國預計2026年市場規模將達6,076億美元。
  • 歐洲：受學名藥和孤兒藥上市的推動，到2025年，該市場規模達到 2,712.1億美元，預計到2026年將達到 2,887.7億美元。
  • 亞太地區：該地區到2025年達到 3,005.7億美元的強勁規模，預計到2026年將達到 3,235億美元。日本、中國和印度是主要貢獻者。
  • 到2025年，拉丁美洲和中東及非洲的經濟成長分別達到 616.4億美元和 333.3億美元，並預計有望持續成長至2034年。

主要企業及趨勢

主要企業包括Novartis AG、Pfizer、Roche、Sanofi、Johnson & Johnson、Merck、AbbVie、GlaxoSmithKline、AstraZeneca，以及專門生產學名藥的公司，例如Dr Reddy's Laboratories和Lupin Pharmaceuticals。近期發展如下：

  • 2023年10月：Novartis公司分拆Sandoz，著重創新藥物。
  • 2023年 1月：Amgen公司在美國推出了其生物相似藥「AMJEVITA」。
  • 2020-2022年：Lupin和Dr. Reddy先後在美國推出了學名藥和專科療法。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要疾病流行情況 - 依主要國家分類，2026年
  • 主要企業管道分析
  • 主要企業的關鍵產業趨勢
  • 主要區域的監管狀況
  • 新產品發布：依主要企業分類
  • 新冠疫情對市場的影響

第5章 2021-2034年全球處方藥市場分析、洞察與預測

  • 市場分析、洞察與預測：依產品類型分類
    • 學名藥
    • 孤兒藥
    • 其他處方藥
  • 市場分析、洞察與預測：依應用領域分類
    • 腫瘤學
    • 中樞神經系統
    • 疫苗
    • 免疫抑制劑
    • 其他
  • 市場分析、洞察與預測：依通路分類
    • 醫院藥房
    • 零售藥局和藥房
    • 網路藥房
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美處方藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲處方藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲國家

第8章 亞太處方藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章 拉丁美洲處方藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東和非洲處方藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2026年）
  • 公司簡介
    • Novartis AG
    • Pfizer, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • AbbVie, Inc.
    • GlaxoSmithKline plc.
    • AstraZeneca
    • CELGENE CORPORATION（BRISTOL-MYERS SQUIBB COMPANY）
Product Code: FBI102709

Growth Factors of prescription drugs Market

The global prescription drugs market was valued at USD 1,324.44 billion in 2025 and is projected to grow to USD 1,415.52 billion in 2026, eventually reaching USD 2,492.84 billion by 2034, reflecting a robust CAGR of 7.33% during the forecast period. North America dominated the market in 2025 with a 49.66% share, primarily driven by high healthcare expenditure, advanced therapies, and the presence of major pharmaceutical companies focusing on generic and specialty medicines. The U.S. prescription drugs market alone is expected to reach USD 931.1 million by 2032, fueled by the increasing approval of orphan drugs and rising demand for specialty medications.

Prescription drugs encompass vaccines, biologics, and therapies used to manage both chronic and acute diseases such as cancer, cardiovascular disorders, diabetes, and rare (orphan) diseases. The market has witnessed significant changes in recent years, including an influx of generic equivalents, impacting overall adoption and accessibility. The COVID-19 pandemic caused a temporary decline in 2020 due to lockdowns, restricted hospital visits, and disruptions in supply chains, leading to shortages and reduced drug expenditures globally. According to the American Society of Health-System Pharmacists, prescription drug spending in nonfederal hospitals fell by 4.6% in 2020. However, the resurgence of routine healthcare services, increased patient visits, and rising R&D initiatives, particularly for COVID-19 treatments, contributed to renewed growth in the market.

Market Trends

Pipeline Expansion Across Therapy Areas

Increasing R&D investments by pharmaceutical companies are a critical trend in the market. In Europe, research-based pharmaceutical companies invested approximately USD 43,684.2 million in R&D in 2021 to develop drugs addressing chronic disorders. Companies are increasingly focusing on rare diseases (orphan drugs), with numerous clinical trials ongoing, which is expected to fuel market growth over the forecast period.

Generic Drug Adoption

The launch of generic equivalents is a key growth driver. In October 2019, the U.S. FDA approved 1,171 generic drugs, enhancing competition and making medications more affordable. Government initiatives, such as India's Aushadhi Scheme, offer generic drugs at 50-90% lower costs, further supporting market expansion.

Orphan Drugs Development

The increasing focus on orphan drugs is another major factor. Companies such as BioMarin and Baudax Bio are developing therapies for rare diseases, with orphan drug approvals enabling accelerated clinical trials and eventual market entry, creating opportunities for blockbuster drugs in previously underserved markets.

Market Restraints

Despite the growth drivers, high costs associated with prescription drugs limit market penetration. Developing a new drug can cost USD 2.6 billion, and certain therapies, such as Abiraterone for prostate cancer, may cost USD 10,000 per month, making affordability a challenge, particularly in developing regions.

Market Segmentation

By Product Type

  • Other Prescription Drugs dominate, accounting for 71.71% globally in 2026, driven by oncology, anti-diabetic, and cardiovascular medications without immediate generic equivalents.
  • Orphan drugs are expected to grow at a higher CAGR, supported by increasing clinical trials and regulatory approvals.
  • Generics benefit from affordability and increasing adoption in emerging markets.

By Therapy

  • Oncology leads, representing 67.55% globally in 2026, due to high cancer prevalence and targeted therapy approvals.
  • Other segments include central nervous system drugs, vaccines, immunosuppressants, and others, all showing growth driven by rising disease prevalence and regulatory approvals.

By Distribution Channel

  • Hospital pharmacies dominate, as critical medications often require professional administration.
  • Retail pharmacies and online pharmacies are growing, with online pharmacies expected to register the highest CAGR due to convenience in prescription refills.

Regional Insights

  • North America: Market size of USD 657.68 billion in 2025, projected to USD 703.04 billion in 2026, led by advanced therapies and high healthcare expenditure. The U.S. is expected to reach USD 607.6 billion in 2026.
  • Europe: Accounted for USD 271.21 billion in 2025, projected to USD 288.77 billion in 2026, driven by generic launches and orphan drugs.
  • Asia Pacific: Strong presence at USD 300.57 billion in 2025, projected to USD 323.5 billion in 2026, with Japan, China, and India being key contributors.
  • Latin America & Middle East & Africa: Represent USD 61.64 billion and USD 33.33 billion respectively in 2025, with steady growth expected through 2034.

Key Companies & Developments

Major players include Novartis AG, Pfizer, Roche, Sanofi, Johnson & Johnson, Merck, AbbVie, GlaxoSmithKline, and AstraZeneca, alongside generic-focused companies like Dr Reddy's Laboratories and Lupin Pharmaceuticals. Recent developments include:

  • October 2023: Novartis spun off Sandoz to focus on innovative medicines.
  • January 2023: Amgen launched biosimilar AMJEVITA in the U.S.
  • 2020-2022: Multiple launches of generic and specialty drugs by Lupin and Dr. Reddy's in the U.S.

Conclusion

The global prescription drugs market is on a sustained growth trajectory from USD 1,324.44 billion in 2025 to USD 2,492.84 billion in 2034, driven by chronic and rare disease prevalence, increased R&D, generic drug adoption, and rising specialty medication approvals. While high costs may restrain some adoption, regional government initiatives, pipeline expansion, and innovations in hospital and homecare therapies ensure robust market expansion. North America remains the dominant market, with Asia Pacific emerging as a high-growth region due to expanding healthcare infrastructure and rising awareness of chronic diseases.

Segmentation By Product Type

  • Generics
  • Orphan
  • Other Prescription Drugs

By Application

  • Oncology
  • Central Nervous System
  • Vaccines
  • Immunosuppressants
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Others

By Geography

  • North America (By Product Type, By Application, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Product Type, By Diabetes Type, By Distribution Channel, and By Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases - By Key Countries/ Region, 2026
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Key Industry Developments, By Key Players
  • 4.4. Regulatory Scenario, By Key Regions
  • 4.5. New Product Launches, By Key Players
  • 4.6. Impact of COVID-19 on the Market

5. Global Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Generics
    • 5.1.2. Orphan
    • 5.1.3. Other Prescription Drugs
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Oncology
    • 5.2.2. Central Nervous System
    • 5.2.3. Vaccines
    • 5.2.4. Immunosuppressants
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies & Drug Stores
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Generics
    • 6.1.2. Orphan
    • 6.1.3. Other Prescription Drugs
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Oncology
    • 6.2.2. Central Nervous System
    • 6.2.3. Vaccines
    • 6.2.4. Immunosuppressants
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies & Drug Stores
    • 6.3.3. Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Generics
    • 7.1.2. Orphan
    • 7.1.3. Other Prescription Drugs
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Oncology
    • 7.2.2. Central Nervous System
    • 7.2.3. Vaccines
    • 7.2.4. Immunosuppressants
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies & Drug Stores
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Generics
    • 8.1.2. Orphan
    • 8.1.3. Other Prescription Drugs
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Oncology
    • 8.2.2. Central Nervous System
    • 8.2.3. Vaccines
    • 8.2.4. Immunosuppressants
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies & Drug Stores
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Generics
    • 9.1.2. Orphan
    • 9.1.3. Other Prescription Drugs
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Oncology
    • 9.2.2. Central Nervous System
    • 9.2.3. Vaccines
    • 9.2.4. Immunosuppressants
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies & Drug Stores
    • 9.3.3. Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Prescription Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Generics
    • 10.1.2. Orphan
    • 10.1.3. Other Prescription Drugs
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Oncology
    • 10.2.2. Central Nervous System
    • 10.2.3. Vaccines
    • 10.2.4. Immunosuppressants
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies & Drug Stores
    • 10.3.3. Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles
    • 11.2.1. Novartis AG
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer, Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. F. Hoffmann-La Roche Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Johnson & Johnson Services, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Merck & Co., Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AbbVie, Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. GlaxoSmithKline plc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. AstraZeneca
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. CELGENE CORPORATION (BRISTOL-MYERS SQUIBB COMPANY)
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 3: Global Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Prescription Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 6: North America Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 7: North America Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Prescription Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 10: Europe Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: Europe Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Prescription Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 14: Asia Pacific Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 15: Asia Pacific Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Prescription Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 18: Latin America Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 19: Latin America Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Prescription Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Prescription Drugs Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 22: Middle East & Africa Prescription Drugs Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 23: Middle East & Africa Prescription Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Prescription Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Prescription Drugs Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034
  • Figure 2: Global Prescription Drugs Market Value Share (%), by Product Type, 2026 & 2034
  • Figure 3: Global Prescription Drugs Market Value Share (%), By Application, 2026 & 2034
  • Figure 4: Global Prescription Drugs Market Value Share (%), by Distribution Channel, 2026 & 2034
  • Figure 5: Global Prescription Drugs Market Value (USD billion), by Region, 2026 & 2034
  • Figure 6: North America Prescription Drugs Market Value (USD billion), by Product Type, 2026 & 2034
  • Figure 7: North America Prescription Drugs Market Value Share (%), by Product Type, 2026
  • Figure 8: North America Prescription Drugs Market Value (USD billion), By Application, 2026 & 2034
  • Figure 9: North America Prescription Drugs Market Value Share (%), By Application, 2026
  • Figure 10: North America Prescription Drugs Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 11: North America Prescription Drugs Market Value Share (%), by Distribution Channel, 2026
  • Figure 12: North America Prescription Drugs Market Value (USD billion), By Country, 2026 & 2034
  • Figure 13: North America Prescription Drugs Market Value Share (%), By Country, 2026
  • Figure 14: Europe Prescription Drugs Market Value (USD billion), by Product Type, 2026 & 2034
  • Figure 15: Europe Prescription Drugs Market Value Share (%), by Product Type, 2026
  • Figure 16: Europe Prescription Drugs Market Value (USD billion), By Application, 2026 & 2034
  • Figure 17: Europe Prescription Drugs Market Value Share (%), By Application, 2026
  • Figure 18: Europe Prescription Drugs Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 19: Europe Prescription Drugs Market Value Share (%), by Distribution Channel, 2026
  • Figure 20: Europe Prescription Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 21: Europe Prescription Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 22: Asia Pacific Prescription Drugs Market Value (USD billion), by Product Type, 2026 & 2034
  • Figure 23: Asia Pacific Prescription Drugs Market Value Share (%), by Product Type, 2026
  • Figure 24: Asia Pacific Prescription Drugs Market Value (USD billion), By Application, 2026 & 2034
  • Figure 25: Asia Pacific Prescription Drugs Market Value Share (%), By Application, 2026
  • Figure 26: Asia Pacific Prescription Drugs Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 27: Asia Pacific Prescription Drugs Market Value Share (%), by Distribution Channel, 2026
  • Figure 28: Asia Pacific Prescription Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 29: Asia Pacific Prescription Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 30: Latin America Prescription Drugs Market Value (USD billion), by Product Type, 2026 & 2034
  • Figure 31: Latin America Prescription Drugs Market Value Share (%), by Product Type, 2026
  • Figure 32: Latin America Prescription Drugs Market Value (USD billion), By Application, 2026 & 2034
  • Figure 33: Latin America Prescription Drugs Market Value Share (%), By Application, 2026
  • Figure 34: Latin America Prescription Drugs Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 35: Latin America Prescription Drugs Market Value Share (%), by Distribution Channel, 2026
  • Figure 36: Latin America Prescription Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 37: Latin America Prescription Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 38: Middle East & Africa Prescription Drugs Market Value (USD billion), by Product Type, 2026 & 2034
  • Figure 39: Middle East & Africa Prescription Drugs Market Value Share (%), by Product Type, 2026
  • Figure 40: Middle East & Africa Prescription Drugs Market Value (USD billion), By Application, 2026 & 2034
  • Figure 41: Middle East & Africa Prescription Drugs Market Value Share (%), By Application, 2026
  • Figure 42: Middle East & Africa Prescription Drugs Market Value (USD billion), by Distribution Channel, 2026 & 2034
  • Figure 43: Middle East & Africa Prescription Drugs Market Value Share (%), by Distribution Channel, 2026
  • Figure 44: Middle East & Africa Prescription Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 45: Middle East & Africa Prescription Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 46: Global Prescription Drugs Market Share (%), By Company, 2026